Abstract 301P
Background
Cervical cancer is the most prevalent reproductive malignancy in women worldwide and estimated over 600,000 new cases and 340,000 deaths each year. Concurrent chemoradiotherapy is the standard treatment for locally advanced cervical cancer. Despite the great improvement this strategy has achieved, nearly 30% of patients will suffer distant metastases and 70% of patients may experience local recurrence. The dominance of Lactobacillus in the vaginal microenvironment of healthy women helps to establish a physiological barrier on the vaginal surface, Microbial biomarkers are effective for predicting the nonresponse for immune checkpoint inhibitor administration. It is intriguing to explore the alteration of vaginal microbial community challenged by chemoradiotherapy, also whether microorganism(s) could be used as biomarkers to predict the responsiveness of chemoradiotherapy.
Methods
A total of 126 patients with IB-IVB cervical cancer who received chemoradiotherapy in our hospital were enrolled in this study. The sampling of vaginal microbiome was carried out as we previously described, both pre- and post-treatment of each patient. Bacterial genomic DNA was extracted and 16S rRNA was sequenced from their vaginal secretions, and the results were analyzed bioinformatically.
Results
We found that the structure and composition of the vaginal microbiome changed significantly before and after radiotherapy, and radiotherapy treatment significantly changed the structure of the microorganisms, destroyed their physiological functions and disrupted the homeostasis of the microbial community. At the same time, we found that the beneficial microbial community in the vaginal microbiome decreased significantly in the relapsing group compared with the non-relapsing group before and after radiotherapy, and the microbial function and community homeostasis were significantly reduced, suggesting an unhealthy vaginal microbiome in the relapsing group.
Conclusions
We have shown that C-reactive protein and disease stage and other factors and biomarkers (such as L. iners) are important factors in predicting the recurrence of cervical cancer patients after radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
Zhejiang medicine and health science and technology project.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract